Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer.

Scientific reports - 9 Aug 2022

Shen Chia-I, Chiang Chi-Lu, Shiao Tsu-Hui, Luo Yung-Hung, Chao Heng-Sheng, Huang Hsu-Ching, Chiu Chao-Hua

Abstract excerpt

Detection of driver gene mutations is important in advanced NSCLC. The cobas EGFR mutation test is a mutant allele-specific real-time PCR assay with limitation owing to its primer design. Next-generation sequencing-based assay has a higher mutation detection coverage; however, its clinical impact remains unclear. We retrospectively collected the records of stage IV NSCLC patients with wild-type EGFR tested by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Diagnosis and Treatment

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed Open full text

Identifiers

PMID: 35945330
DOI: 10.1038/s41598-022-17394-7
PMCID: PMC9363455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer.PMID 35945330Read ↗

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.Semantic proximity Read ↗

The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.Semantic proximity Read ↗

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Semantic proximity Read ↗

Possible False Results With cobas® EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.Semantic proximity Read ↗

A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancerSemantic proximity Read ↗

EGFR Mutation Detection in Brazilian Patients With Non-Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing.Semantic proximity Read ↗

Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.Semantic proximity Read ↗

EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC.Semantic proximity Read ↗

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories.Semantic proximity Read ↗

Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.